24Feb 2024
Sublingual Edaravone Dexborneol Improves Stroke Outcome: Study

Sublingual Edaravone Dexborneol Improves Stroke Outcome: Study

A study investigated sublingual edaravone dexborneol's efficacy in acute ischemic stroke (AIS) patients. Administered twice daily for 14 days, patients on the regimen showed significantly better 90-day functional outcomes compared to the placebo group. The treatment group displayed a higher proportion of patients with favorable outcomes (64.4% vs. 54.7%). This multitarget brain cytoprotection offers promising prospects in AIS management, potentially revolutionizing stroke treatment strategies.

  • #neurology

Like

Save

Share